Trial
NCT04830735
Dasatinib for the Treatment of Moderate and Severe COVID-19
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Southern California
Collaborators
National Cancer Institute (NCI)
Condition
Symptomatic COVID-19 Infection Laboratory-Confirmed
Intervention
Dasatinib Anhydrous
Why stopped
PI decided not to pursue study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-10